Bold BeiGene coming good on affordable innovation vow

The progress quietly made by Sino-American biotech company BeiGene (Nasdaq: BGNE) with its oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) since 2019 has been nothing short of remarkable.

Impressive late-stage data readouts and regulatory approvals have come thick and fast in the indications of chronic lymphocytic leukemia or small lymphocytic leukemia, mantle cell lymphoma and relapsed or refractory marginal zone lymphoma who have received at least one prior therapy, and Waldenström’s macroglobulinemia.

Brukinsa has also outperformed AbbVie’s (NYSE: ABBV) Imbruvica (ibrutinib), which has been the standard of care in chronic lymphocytic leukemia, for almost a decade.